Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 776 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Solid Neoplasm Clear all
Completed Phase 2 Interventional

Paclitaxel in Treating Women With Recurrent Solid Tumors

NCT00003130
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
34
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00004864
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
GEM 231, docetaxel
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Oct 21, 2026, 2:46 PM EDT
Completed No phase listed Observational

iCAT for Recurrent/Refractory/HR Solid Tumors

NCT01853345
View directory record Official record
Conditions
Pediatric Solid Tumor, Sarcoma, Neuroblastoma, Wilms Tumor
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

NCT00004212
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
filgrastim, exatecan mesylate
Biological · Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

NCT01495663
View directory record Official record
Conditions
Cancer
Interventions
I-131-CLR1404
Drug
Lead sponsor
Cellectar Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Duarte, California • Washington D.C., District of Columbia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

NCT00544284
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, temozolomide, pharmacological study
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 21, 2026, 2:46 PM EDT
Terminated Phase 2 Interventional

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

NCT03066206
View directory record Official record
Conditions
EGFR Exon 20 Mutation, ERBB2 Gene Mutation, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Poziotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors

NCT01129349
View directory record Official record
Conditions
Solid Tumors
Interventions
Oprozomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Nashville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 21, 2026, 2:46 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer

NCT02842125
View directory record Official record
Conditions
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Interventions
Ad-P53, Xeloda, Keytruda, Opdivo
Drug
Lead sponsor
MultiVir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 21, 2026, 2:46 PM EDT
Recruiting No phase listed Observational

Registry of Older Patients With Cancer

NCT01137825
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2030
U.S. locations
7
States / cities
Boone, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Terminated Phase 1 Interventional

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

NCT01122888
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Solid Neoplasm, Recurrent Adult Brain Neoplasm
Interventions
Cilengitide, Clinical Observation, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 21, 2026, 2:46 PM EDT
Terminated Phase 1 Interventional

BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00028561
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ixabepilone, carboplatin, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Oct 21, 2026, 2:46 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

NCT03212274
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
51
States / cities
Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

NCT00020046
View directory record Official record
Conditions
Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Male only
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 21, 2026, 2:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

NCT02963610
View directory record Official record
Conditions
Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Interventions
Lenalidomide, Pembrolizumab
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 21, 2026, 2:46 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

NCT03544723
View directory record Official record
Conditions
Solid Tumor, Lymphoma
Interventions
Ad-p53
Drug
Lead sponsor
MultiVir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 21, 2026, 2:46 PM EDT
Terminated Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

NCT00023790
View directory record Official record
Conditions
Breast Cancer, Head and Neck Cancer, Lymphoma, Metastatic Cancer, Non-melanomatous Skin Cancer, Sarcoma
Interventions
silicon phthalocyanine 4
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Depsipeptide in Treating Patients With Solid Tumors

NCT00019318
View directory record Official record
Conditions
Lymphoma
Interventions
romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

NCT00003406
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
carboplatin, docetaxel, ifosfamide, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Up to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01154816
View directory record Official record
Conditions
Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Kidney Neoplasm, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma
Interventions
Alisertib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
97
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 78 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 21, 2026, 2:46 PM EDT
Recruiting Phase 1 Interventional

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

NCT04693468
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Axitinib, Crizotinib, Palbociclib Isethionate, Talazoparib Tosylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00734890
View directory record Official record
Conditions
Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bevacizumab, vandetanib, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Anhydrovinblastine in Treating Patients With Advanced Recurrent Solid Tumors

NCT00003882
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
anhydrovinblastine
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

NCT04447755
View directory record Official record
Conditions
Relapsed or Refractory Solid Tumors
Interventions
Lenvatinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 21 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Aurora, Colorado • Cleveland, Ohio • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 21, 2026, 2:46 PM EDT